Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn-Currently Amended) A percutaneous absorption type cerebral protective agent comprising, as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof in ~~a base.~~ an aqueous base, the aqueous base comprising, based on a total amount of the aqueous base:

1 to 20 percent by mass of a water-soluble polymer,

0.01 to 20 percent by mass of a cross-linking agent,

10 to 80 percent by mass of polyhydric alcohol, and

1 to 80 percent by mass of water,

wherein the percutaneous absorption type cerebral protective agent comprises one or more of talc, lactic acid, isopropanol and polysorbate 80.

2-5. (Canceled)

6. (Withdrawn-Currently Amended) A method of manufacturing a pharmaceutical composition, the method comprising:

combining a percutaneous absorption type pharmaceutical composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof with ~~a base~~ an aqueous base in an amount of 0.1 to 30 percent by ~~mass.~~ mass, the aqueous base comprising, based on a total amount of the aqueous base:

1 to 20 percent by mass of a water-soluble polymer,

0.01 to 20 percent by mass of a cross-linking agent,

10 to 80 percent by mass of polyhydric alcohol, and

1 to 80 percent by mass of water,

wherein the percutaneous absorption type pharmaceutical composition comprises one or more of talc, lactic acid, isopropanol and polysorbate 80.

7-10. (Canceled)

11. (Currently Amended) A method of protecting against cerebral dysfunction, comprising:

administering to a patient a percutaneous absorption type pharmaceutical composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof,

the active ingredient being present in an amount of 0.1 to 30 percent by mass in an aqueous base, the aqueous base comprising, based on a total amount of the aqueous base:

1 to 20 percent by mass of a water-soluble polymer,

0.01 to 20 percent by mass of a cross-linking agent,

10 to 80 percent by mass of polyhydric alcohol, and

1 to 80 percent by mass of ~~water.~~ water,

wherein the percutaneous absorption type pharmaceutical composition comprises one or more of talc, lactic acid, isopropanol and polysorbate 80.

12–15. (Canceled)

16. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition further comprises n-methyl-2-pyrrolidone or crotamiton as a dissolving agent.

17. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

18. (Previously Presented) The method according to claim 16, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

19. (Previously Presented) The method according to claim 16, wherein the dissolving agent is crotamiton.

20. (Previously Presented) The method according to claim 19, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

21. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises talc.

22. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises lactic acid.

23. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises isopropanol.

24. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises polysorbate 80.